Book Value per Share: Zymeworks Corp (ZYME)

Graphic logo of Zymeworks (ZYME)

Zymeworks Inc. (ZYME) develops complex antibodies to combat tumors, targeting the B2B segment and major pharmaceutical partners. The company outsources manufacturing processes and clinical trials to external contractors to maintain a focus on innovation. This price chart reflects the asset's dynamics, with a value of 1.13. Through milestone payments, the business effectively scales profits, minimizing the impact of fixed costs via operating leverage.

ZYME: Zymeworks Corp Net Asset Value per Share 07/04/2022 - 10/27/2026

zymeworks.com - analytical breakdowns and key metrics (ZYME)

- price and consensus price forecast:
Price Chart Zymeworks Corp|ZYME - Consensus Target
- market capitalization data:
Market Capitalization Zymeworks Inc.|ZYME - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Zymeworks|ZYME - Total Stockholders' Equity|Market Value to Book Value Ratio zymeworks.com|ZYME - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Zymeworks Inc.|ZYME - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Zymeworks|ZYME - Company Cumulative Debt|Debt to Book Capitalization Ratio Zymeworks Inc.
Fundamental company valuation:ZYME - Zymeworks Corp
Flagship merchandise of Zymeworks

Book value per share determines the intrinsic value of a business, reflecting the portion of equity attributable to a single owner. This metric is calculated by dividing net assets minus liabilities by the number of outstanding shares. By analyzing the book value per common share trend, an investor can gauge the issuer's actual tangible stability. For Zymeworks Inc. (ZYME), this basis is bolstered by a strong reputation in the development of targeted antibodies, as partner confidence capitalizes the company's intellectual assets.

Competitor analysis for Zymeworks Inc.

IBRX: Net Assets per Single Share|IMCR - Accounting Value per Share|Book Value per Share JANX|RCUS (arcusbio.com) - Net Asset Value per Share|Net Assets per Single Share TNGX (Tango Therapeutics, Inc.)|Net Asset Value per Share IOVA|Net Assets per Single Share Immatics Corp IMTX|Equity per Share Xencor Inc. (XNCR)|Compass Therapeutics - Book Value per Share|replimune.com - Accounting Value per Share|LYEL (Lyell Immunopharma, Inc.) - Net Assets per Single Share|IPHA: Net Asset Value per Share|pyxisoncology.com (PYXS) - Net Assets per Single Share|CGEN (Compugen) - Net Assets per Single Share|Net Assets per Single Share IOBT (IO Biotech, Inc.)|Net Asset Value per Share sutrobio.com|INKT: Book Value per Share|Book Value of One Share werewolftx.com HOWL|IMMX: Accounting Value per Share|ALXO - Net Asset Value per Share|Accounting Value per Share Cue Biopharma, Inc. (CUE)|PDSB - Accounting Value of a Share|sonnetbio.com - Book Value per Share|MAIA (MAIA Biotech) - Net Assets per Share|Net Assets per Single Share LIMN|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx